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ABSTRACT
Background
In falciparum malaria sequestration of erythrocytes containing mature forms of Plasmodium
falciparum in the microvasculature of vital organs is central to pathology, but quantitation of
this hidden sequestered parasite load in vivo has not previously been possible. The peripheral
blood parasite count measures only the circulating, relatively non-pathogenic parasite
numbers. P. falciparum releases a specific histidine-rich protein (PfHRP2) into plasma.
Quantitative measurement of plasma PfHRP2 concentrations may reflect the total parasite
biomass in falciparum malaria.
Methods and Findings
We measured plasma concentrations of PfHRP2, using a quantitative antigen-capture
enzyme-linked immunosorbent assay, in 337 adult patients with falciparum malaria of varying
severity hospitalised on the Thai–Burmese border. Based on in vitro production rates, we
constructed a model to link this measure to the total parasite burden in the patient. The
estimated geometric mean parasite burden was 7 3 10
11 (95% confidence interval [CI] 5.8 3
10
11 to 8.5 3 10
11) parasites per body, and was over six times higher in severe malaria
(geometric mean 1.7 3 10
12, 95% CI 1.3 3 10
12 to 2.3 3 10
12) than in patients hospitalised
without signs of severity (geometric mean 2.8 3 10
11, 95% CI 2.3 3 10
11 to 3.5 3 10
11; p ,
0.001). Parasite burden was highest in patients who died (geometric mean 3.4 3 10
12, 95% CI
1.9 3 10
12 to 6.3 3 10
12; p ¼ 0.03). The calculated number of sequestered parasites increased
with disease severity and was higher in patients with late developmental stages of P. falciparum
present on peripheral blood smears. Comparing model and laboratory estimates of the time of
sequestration suggested that admission to hospital with uncomplicated malaria often follows
schizogony—but in severe malaria is unrelated to stage of parasite development.
Conclusion
Plasma PfHRP2 concentrations may be used to estimate the total body parasite biomass in
acute falciparum malaria. Severe malaria results from extensive sequestration of parasitised
erythrocytes.
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Histidine-rich protein 2 (PfHRP2) is a 30-kDa protein
produced by Plasmodium falciparum [1,2]. PfHRP2 is found in
the parasite cytoplasm or parasite food vacuole, where it may
play a role in the polymerization of heme to hemozoin [3,4]. It
is also found in the host erythrocyte cytoplasm and red cell
membrane [5]. PfHRP2 is released from infected erythrocytes
as a water-soluble protein both in vivo and in vitro [6,7].
Sequestration of parasitised erythrocytes in the second half
of the asexual life cycle (mature trophozoite and schizont
stages) in the microvasculature of vital organs compromises
the microcirculation, and is a central feature in the patho-
genesis of falciparum malaria. Peripheral blood parasitaemia
is very widely used to assess disease severity in malaria, but it is
only a weak predictor of mortality in falciparum malaria, as
the less pathogenic circulating stages can be counted whereas
the more pathogenic sequestered mature parasitised eryth-
rocytes are not seen and therefore not counted by the
microscopist. These sequestered parasites secrete PfHRP2
into the plasma, and PfHRP2 is liberated at schizont rupture.
The plasma concentration of this protein might therefore
provide a better estimate for the patient’s total parasite
biomass, and hence be an accurate prognostic indicator. In a
recent study we measured PfHRP2 quantitatively in synchron-
ized P. falciparum cultures, and showed that approximately
89% of PfHRP2 is liberated at schizont rupture and that the
variation in the amount released is limited [8]. In the current
study we quantiﬁed plasma PfHRP2 concentrations in
patients with falciparum malaria and, using a simple mathe-
matical model, applied this approach to estimate the total
body parasite biomass. We then related this to parameters of
disease severity and outcome. Since the developmental stage
distribution of circulating parasites also provides information
on the sequestered parasites [9], this was also evaluated in
relation to plasma PfHRP2 levels in these patients.
Methods
Patients
In total 170 patients with uncomplicated malaria and 167
patients with severe malaria who participated in antimalarial
treatment studies in Sangklaburi Hospital in western Thai-
land and in Mae Sot Hospital in northwestern Thailand were
included in the study. These are low, seasonal transmission
areas. Severe disease is seen in patients of all ages. Disease
severity was classiﬁed using a modiﬁcation of deﬁnitions
employed by Hien et al. [10]. Patients were classiﬁed as having
severe malaria if they met one of the following criteria: (a)
Glasgow Coma Score (GCS) , 11, (b) hematocrit (Hct)
100,000/ll, (c) jaundice with bilirubin . 42.8 lmol/l and with
parasite count . 100,000/ll, (d) serum creatinine . 265 lmol/
l with urine output , 400 ml/24 h, (e) hypoglycaemia with
venous glucose , 2.2 mmol/l, (f) systolic blood pressure , 80
mm Hg with cool extremities, (g) peripheral asexual stage
parasitaemia . 10%, (h) peripheral venous lactate . 4 mmol/
l, or (i) peripheral venous bicarbonate , 15 mmol/l. Patients
without any of these features were considered to have
uncomplicated malaria, even when the clinical severity was
still sufﬁcient to warrant admission to hospital. Heparinised
plasma samples were collected on admission from these
patients and stored at 70 8C until PfHRP2 assay. A complete
blood cell count was made at the same time, and blood ﬁlms
were stained with Field’s stain for parasite count and staging.
Mixed infections with other Plasmodium species were ex-
cluded. The stage of P. falciparum parasite development on
blood ﬁlms was assessed as described previously [11] and
divided into seven different age groups (tiny rings 0–6 h,
small rings 6–16 h, large rings 16–26 h, early trophozoites 26–
30 h, middle trophozoites 30–34 h, late trophozoites 34–38 h,
and schizonts 38–48 h) [11]. Basic biochemistry and plasma
glucose and lactate levels were assessed on all admission
samples. Patients were treated with oral artesunate and
meﬂoquine for uncomplicated disease or with intravenous
quinine or artesunate for severe malaria, and managed
according to standard procedures [12,13]. All patients or
their attendant relatives gave fully informed written consent
to blood sampling. The patients were enrolled in a series of
prospective studies approved by the ethical review subcom-
mittee of the Thai Ministry of Public Health.
PfHRP2 Enzyme-Linked Immunosorbent Assay
All samples were tested with the malaria Ag Celisa kits
(Cellabs, Sydney, New South Wales, Australia) employing a
sandwich ELISA. These kits utilize a monoclonal-antibody-
based assay speciﬁc for P. falciparum and detect PfHRP2
antigen produced by the parasite. The assay was performed
following the manufacturer’s instruction. Brieﬂy, microwells
were precoated with anti–P. falciparum monoclonal capture
antibody. Plasma samples in serial 2-fold dilutions together
with positive and negative controls (100 ll) were added to the
wells and incubated for 1 h at room temperature, followed by
anti-falciparum antibody conjugate (diluted 1:200). Finally,
tetramethyl benzidine substrate was added, and the sample
was incubated for 15 min at room temperature. The reaction
was then stopped by adding 2 M sulfuric acid, and the results
were read spectrophotometrically at 450 nm in a Bio-Tek
ELX 808 TM plate reader (Bio-Tek Instruments, Winooski,
Vermont, United States). The cut-off level for deﬁning a
reading as positive was set at the absorbance value of the
negative control plus 0.1 unit, as recommended by the
manufacturer of the test kit. A positive reading for PfHRP2
antigen was deﬁned as an absorbance value above the cut-off
level. Puriﬁed PfHRP2 (kindly provided by D. Sullivan, John
Hopkins School of Public Health) diluted in either normal
human plasma or PBS-TWEEN at decreasing concentrations
was also assayed to construct a titration curve and to
determine the sensitivity of the test. Titration curves were
similar for human plasma and PBS-TWEEN as diluents, and
the titration curve was used to convert titres to actual
concentrations of PfHRP2. The lowest detection limit of
puriﬁed PfHRP2 was 1.5 ng/ml.
Calculation of Total Body Parasite Biomass
In our previous study we showed that PfHRP2 is secreted in
a stage-dependent manner by parasitised erythrocytes. In in
vitro studies of four carefully synchronized cultures, the
median (range) amount of PfHRP2 secreted per parasite per
erythrocytic cycle was 5.2310
 15 g (1.1310
 15 to 13.0310
 15
g). A median of 89%, or 4.6310
 15 g, of the total PfHRP2 was
liberated at schizont rupture; the remaining 11%, or 0.6 3
10
 15 g, was secreted almost entirely in the second half of the
48-h erythrocytic cycle [8].
Since the in vivo plasma elimination kinetics of PfHRP2
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tions and parasite biomass, the kinetics of PfHRP2 was studied
in 13 adult patients with falciparum malaria admitted in the
Bangkok Hospital for Tropical Diseases, Bangkok, Thailand,
ten of whom fulﬁlled the criteria for severe disease [10]. Two
patientshadcerebralmalaria(GCS,11),threewerejaundiced
(serum bilirubin . 42.8 lmol/l), and two had renal failure
(serum creatinine . 265 lmol/l). Plasma PfHRP2 concentra-
tions were measured on admission, and then on days 1, 3, 7, 14,
21, and 21 after admission. The data were analysed using the
WinNonlin statistical package (Pharsight, Mountain View,
California, United States). There was no evidence of concen-
tration dependence, and a single exponent term gave the best
ﬁt to the decline in plasma PfHRP2 concentrations with time
(i.e., elimination of PfHRP2 was a ﬁrst-order process). The
mean (standard deviation) plasma elimination half-life (t½) of
PfHRP2 was 3.67 (1.47) d, or 1.84 erythrocytic cycles, and was
notcorrelatedwithmeasuresofdiseaseseverityorbiochemical
evidence of renal or hepatic dysfunction.
This information was used to construct a model to derive
parasite numbers from the plasma PfHRP2 concentrations
(Figure 1). It was assumed that patients were infected with a
single relatively synchronous unimodal infection of P.
falciparum [9]. Immediately following schizont rupture,
released merozoites will infect new erythrocytes, expanding
the infection with a multiplication factor M. If the number of
parasites in the generation present at the moment of blood
sampling is P, the number of parasites at the moment of the
previous schizont rupture will be P/M. These parasites will
release an amount of PfHRP2 (A, in grams) of 4.6310
 15 P/M
into the circulation, giving a concentration of A/Vd, where Vd
represents the volume of distribution of PfHRP2. As PfHRP2
is a relatively large molecule (30 kDa), it was assumed that Vd
equalled the plasma volume, which is (100   Hct) 3 total
blood volume. The total blood volume was estimated to be 80
ml/kg body weight.
As assessed in the pilot study described above, PfHRP2
elimination followed a ﬁrst-order process, with a half-life (t½)
of 3.67 d, or, for a 2-d cycle, 1.84 erythrocytic cycles,
corresponding to an elimination constant k ¼ 0.693/t½ ¼
0.377/asexual cycle. The concentration of PfHRP2 (in grams/
litre) released at the moment of schizont rupture (CR) will
then be given by the formula
CRðtÞ¼
4:6310 15Pe kt
MVd
ð1Þ
In the second half of the subsequent cycle, during the
trophozoite and schizont stages, a total amount of 0.6310
 15
g of PfHRP2 per parasite will be released into the circulation
by the newly infected erythrocytes. This production was
assumed to be at a constant rate (1.2 3 10
 15 g per parasite
per cycle time) in the second half of the cycle. With time
expressed as units of asexual cycle length and the elimination
constant k ¼ 0.377/cycle, the concentration CTS of PfHRP2
derived from these mature parasites during the second half of
the erythocytic cycle will be given by the formula
CTSðtÞ¼
Rð1   e kðt 0:5ÞÞ
kVd
ð2Þ
where R is the rate at which PfHRP2 is secreted into the
plasma, equalling 1.2 3 10
 15 P g per cycle, so that
CTSðtÞ¼
1:2310 15Pð1   e kðt 0:5ÞÞ
kVd
ð3Þ
If C0 is the concentration of PfHRP2 derived from the
current cycle, C0 ¼ CR for the ﬁrst half of the cycle, derived
from schizont rupture of the previous cycle, and C0¼CRþCTS
during the second half of the cycle, derived from the residual
amount released at schizont rupture and from release by
trophozoites and schizonts from the present cycle. Since all
blood samples were taken on admission, even if the patient
was admitted during the night, it was assumed that blood
samples were drawn randomly during the erythrocytic cycle
of the parasite. The average concentration of PfHRP2 ( C0)
will thus be the area under the concentration–time curve
divided by the time span of the erythrocytic cycle of the
parasite generation present at the moment of blood
sampling. For one cycle from t ¼ 0 until t ¼ 1, this will
equal
 C0 ¼
Z t¼1
t¼0
CRðtÞdtþ
Z t¼1
t¼0:5
CTSðtÞdt ð4Þ
Substituting equations 1 and 3 into this equation, this can be
solved to
 C0 ¼
4:6310 15Pð1   eð kÞÞ
MVdk
þ
1:2310 15Pð0:5k   1 þ eð 0:530:377ÞÞ
Vdk2 ð5Þ
However, PfHRP2 accumulated from the erythrocytic
cycles before the cycle during which the blood sample was
taken will also contribute to the observed concentration of
PfHRP2, because the elimination half-life exceeds the asexual
cycle length. If  C1 is the concentration of PfHRP2 derived
from the cycle previous to the cycle at the moment of blood
Figure 1. Model Describing the PfHRP2 Concentration Derived from 10
12
Total Body Parasites in the Last Cycle
Total PfHRP2 derives from the amount produced by the generation
present in that cycle and the amount produced at schizont rupture of
the previous cycle (broken lines). The concentration accumulated from
previous production is added to this (black lines). PfHRP2 produced in
previous cycles will decline over time (dotted lines). Values chosen for
the parameters in this illustration were as follows: Hct, 0.35; body weight,
50 kg; and parasite multiplication factor, eight.
DOI: 10.1371/journal.pmed.0020204.g001
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previous cycle will be  C0=M, and because of the exponential
decline described by k, the average amount left in the next
cycle will be e kð C0=MÞ.
For the n
th previous cycle, the formula to calculate the
contribution to the observed concentration of PfHRP2 can be
generalized by induction to
 Cn ¼
e kn
Mn
 C0 ð6Þ
The total expected PfHRP2 concentration observed in a
peripheral blood sample ( Cobs) can thus be expressed as
 Cobs ¼ C0
X n
n¼1
e kn
Mn ð7Þ
which can be solved to
 Cobs ¼
 C0M
M   e k ð8Þ
Substituting equation 8 into equation 5 provides an
explicit expression for the overall concentration as a function
of the parameters:
Cobs ¼
4:6310 15kð1   e kÞ
Vdk2ðM   e kÞ
 
þ
1:2310 15Mð0:5k   1 þ e 0:5kÞ
Vdk2ðM   e kÞ
 
3P ð9Þ
Figure 1 gives a graphic summary of the model.
Rearrangement of equation 9 gives an explicit expression
for the total parasite load Ptot as a function of the measured
concentration:
Ptot ¼
 CobsVdk2ðM   e kÞ31015
4:6kð1   e kÞþ1:2Mð0:5k   1 þ e 0:5kÞ
ð10Þ
For the calculations of total body parasite biomass, an in
vivo multiplication rate of eight was assumed. This is the
average derived multiplication rate observed at detectable
parasitaemias in patients with acute malaria in experimental
infections before treatment [14]. Substituting these values
into equation 10, and with the elimination constant k¼0.377,
the total body number of parasites (Ptot) can now be
calculated for a measured plasma PfHRP2 concentration
(Cobs, in grams/litre):
Ptot ¼
0:933Cobs 3Vd 31015
0:62
ð11Þ
Vd (in litres) was estimated as (1   Hct) 3 80 3 10
 3 3 body
weight (in kilograms), equalling the estimated plasma volume,
so that
Ptot ¼ 12Cobsð1   HctÞ3body weight31013 ð12Þ
The total circulating number of parasites (Pcir) was
calculated from the observed peripheral blood parasitaemia
(percent) in the peripheral blood thin smear multiplied by
the estimated total body red blood cell mass. Assuming a total
blood volume of 80 ml/kg body weight, total body red blood
cell mass was estimated as
Hct3803body weight
MRCV
ð13Þ
where MRCV is the mean red blood cell volume.
The estimated number of sequestered parasites was
calculated as the difference between the estimated total
parasite biomass and the total circulating parasite biomass.
The model was subjected to uncertainty and sensitivity
analysis with the following parameters as variables: (a)
multiplication rate (M), the distribution of which was chosen
to be uniform between one and ten; (b) PfHRP2 half-life (t½),
normally distributed with a mean of 3.7 d and a standard
deviation of 1.47 d, derived from the pilot study described
above; (c) the amount of PfHRP2 released per cycle, normally
distributed with a mean of 5.2 3 10
 15 g and a standard
deviation of 2.0 3 10
 15 g (from [8]). The ﬁxed parameters
included: Hct¼0.35% and body weight¼50 kg, giving a Vd of
2.6 litres and an observed plasma PfHRP2 concentration of
1,000 3 10
 6 g/l. Using these parameters 10,000 simulations
were performed using the S-PLUS mathematical program
(Insightful, Seattle, Washington, United States), with the
predicted total parasite biomass as outcome. This showed
that the predicted parasite biomass was log-normally dis-
tributed with a geometric mean of 2.9310
12. The coefﬁcient
of variation of the log-transformed outcome was 3%,
indicating a high level of consistency.
The partial rank correlation coefﬁcients between each
parameter and the outcome of the model were 0.64,  0.10,
and  0.48 for multiplication rate, PfHRP2 half-life, and the
amount of PfHRP2 secreted per cycle, respectively. This
indicates that multiplication rate was the most inﬂuential
factor affecting the total parasite biomass estimate, followed
by the amount of PfHRP2 secreted per cycle. The variation in
PfHRP2 half-life had only a small effect on the calculations.
To illustrate the impact of the multiplication rate on the
model, Figure 2 shows the total body number of parasites for
a patient with a plasma PfHRP2 concentration of 1310
 3 g/l,
Hct of 0.35%, and a body weight of 50 kg at different parasite
multiplication rates.
Statistical Analysis
Data were analysed using SPSS for Windows release 10.05
(SPSS, Chicago, Illinois, United States). Continuous variables
that were not normally distributed were log-transformed. The
Figure 2. Estimated Total Parasite Biomass as a Function of the Parasite
Multiplication Rate, Using the Model Described in the Text
Values chosen for the parameters were as follows: PfHRP2 concentration,
1,000 lg/l; Hct, 0.35; and body weight, 50 kg.
DOI: 10.1371/journal.pmed.0020204.g002
PLoS Medicine | www.plosmedicine.org August 2005 | Volume 2 | Issue 8 | e204 0791
PfHRP2 and Malaria Parasite Biomasslaboratory ﬁndings in the uncomplicated and severe groups
were assessed using Student’s t-tests for normal distributed
parameters. Correlation was assessed by the methods of
Pearson or Spearman as appropriate. Logistic regression was
used to determine the relationship between mortality and
plasma PfHRP2 or other prognostic factors including plasma
haemoglobin, creatinine, lactate, bilirubin, and glucose
concentrations.
Results
PfHRP2 Detection
The lowest limit of detection of puriﬁed PfHRP2 was 1.53
10
 6 g/l. The titration curves were similar when normal
human plasma or PBS-TWEEN was used as the diluent. The
mean (95% CI) plasma PfHRP2 concentration in 337 patients
with falciparum malaria was 8.4310
 4 g/l (5.7310
 4 to 11.13
10
 4 g/l).
Patient Characteristics
A total of 337 adult patients with falciparum malaria were
enrolled over a period of 10 y. Patient characteristics are
summarised in Table 1. According to the modiﬁed World
Health Organization criteria adapted from Hien et al. [10],
167 patients had severe disease, of whom 28 (17%) died. Of
the patients with severe disease 107 (64%) had cerebral
malaria, deﬁned as a GCS below 11. Twenty-two (13%) had
renal failure (plasma creatinine . 265 lmol/l and diuresis ,
400 ml/ 24 h), 87 (52%) were jaundiced (total plasma bilirubin
. 42.8 lmol/l), and 73 (44%) had a plasma lactate above 5
mmol/l. Eight (5%) patients were shocked on admission
(systolic blood pressure below 80 mm Hg, with cold
extremities). No patient had an admission Hct below 20%.
Seventy-two patients (43%) were hyperparasitaemic (.10%
of red cells parasitised) as assessed in the peripheral blood
slide on admission. Pre-treatment before admission with
antimalarial drugs was infrequent and did not differ
signiﬁcantly between patients with severe versus uncompli-
cated disease. In the group with uncomplicated malaria (n ¼
170), three patients were treated with chloroquine (which is
completely ineffective in this area), two received one dose of
an artemisinin-containing drug, two received a single dose of
quinine, and in two patients an unknown antimalarial was
taken. For the patients with severe disease (n ¼ 167), the
corresponding numbers were as follows: four patients were
pre-treated with chloroquine, one with sulphadoxine-pyri-
methamine (also ineffective), two with a single dose of
quinine, and in another six patients an unknown antimalarial
was taken. So only seven out of 337 patients were docu-
mented to be treated with an effective antimalarial drug, and
in none was the dose curative.
Estimated Total Body Parasite Biomass Compared to
Peripheral Blood Parasitaemia and Parasite
Developmental Stage
Applying the model described above, the peripheral blood
plasma concentration of PfHRP2 was used to estimate the
total body parasite burden in 337 adult patients with
falciparum malaria, assuming a uniform in vivo multi-
plication rate of eight (Figure 2). The geometric mean of
the total parasite load for all patients was 7.0 3 10
11 (95% CI
5.8 3 10
11 to 8.5 3 10
11) parasites/body (Figure 3). When the
total parasite load was related to the estimated total red
blood cell mass, the geometric mean whole body parasitaemia
was 46 per 1,000 (95% CI 38 to 57 per 1,000) erythrocytes.
The geometric mean of the simultaneously assessed periph-
Table 1. Characteristics of Studied Patients
Characteristic Uncomplicated Severe (Survivors) Fatal Cases
Sample size 170 139 28
Age (y) 30 (27–33) 29 (27–32) 26 (21–32)
Systolic blood pressure (mm Hg) 108 (101–114) 107 (98–116) 113 (97–124)
GCS
a 15 (11–15) 15 (3–15) 7 (3–15)
Hct (%) 0.37 (0.35–0.39) 0.33 (0.31–0.35) 0.33 (0.28–0.38)
Serum bilirubin (lmol/l)
a 22.2 (3.4–456.6) 49.6 (5.1–649.8) 124.8 (10.3–658.4)
Serum creatinine (lmol/l) 101.7 (94.6–108.7) 140.6 (118.5–162.7) 300.6 (157.4–443.8)
Plasma lactate (mmol/l) 2.1 (1.9–2.3) 4.9 (4.3–5.7) 9.6 (7.6–11.8)
Peripheral asexual parasitaemia (/ll)
b 62,574 (50,095–78,144) 206,395 (156,458–272,332) 224,646 (133,751–377,311)
Peripheral trophozoites and schizonts (/ll)
b 58 (29–115) 605 (260–1,407) 6,302 (953–41,668)
Values are mean (95% CI) except as otherwise noted.
aMedian (range).
bGeometric mean (95% CI).
DOI: 10.1371/journal.pmed.0020204.t001
Figure 3. Total (Log10) Parasite Biomass Estimated from Plasma PfHRP2
Concentrations in a Peripheral Blood Sample in 337 Patients with
Falciparum Malaria
DOI: 10.1371/journal.pmed.0020204.g003
PLoS Medicine | www.plosmedicine.org August 2005 | Volume 2 | Issue 8 | e204 0792
PfHRP2 and Malaria Parasite Biomasseral blood parasitaemia for all patients was 28 per 1,000 (95%
CI 25 to 33 per 1,000) erythrocytes.
When the numbers of sequestered parasites were calculated
(by subtraction) a negative value was obtained in 22% of the
patients; in these cases patients were assumed to have very
few or no sequestered parasites. The median number of
sequestered parasites obtained in this way for all malaria
cases was 2.5 3 10
11 (interquartile range 4.7 3 10
9 to 1.5 3
10
12) parasites/body.
The number of sequestered parasites was also assessed in
relation to the parasite stage in the peripheral blood smear.
We have reported previously that in patients with severe
malaria a predominance of mature stages (trophozoites and
schizonts) in the peripheral blood (.10
4/ll) is associated with
a fatal outcome, presumably because this reﬂects a stage
distribution of more mature parasites composing the total
parasite burden and thus a greater sequestered parasite
biomass [9,11]. Using the previous cut-off value of .10
4/ll
mature-stage parasites in the peripheral blood, the number of
sequestered parasites in patients with severe malaria (median
[interquartile range]) was four times higher if mature-stage
parastites predominated (n ¼ 79); 1.6 3 10
12 (2.5 3 10
11 to 5.4
310
12) parasites compared with 4.0310
11 (6.73 10
9 to 2.13
10
12) parasites if mature-stage parasites did not predominate
(p¼0.002 by Mann-Whitney U test) (Figure S1). Overall there
was a positive correlation between the proportion of late-
stage parasites in the peripheral blood slide and the
calculated proportion of sequestered parasites from the
model (Spearman correlation, rs ¼ 0.41, p , 0.001).
Estimated Total Parasite Biomass and Severity of Disease
The estimated total parasite biomass increased in propor-
tion to severity of the disease.The geometric mean (95% CI)
parasite load was six times lower in patients hospitalised
without evidence of severe malaria than in patients with
severe malaria: 2.8310
11 (2.3310
11 to 3.5310
11) versus 1.73
10
12 (1.3 3 10
12 to 2.3 3 10
12) parasites/body (p , 0.001).
Within the group of patients with severe malaria, those who
died (n¼28) had over twice the geometric mean parasite load
compared with patients who survived (n ¼ 139): 3.4 3 10
12
(95% CI 1.9310
12 to 6.3310
12) versus 1.5310
12 (95% CI 1.2
3 10
12 to 2.0 3 10
12) parasites/body (p ¼ 0.03 with Bonferroni
correction for multiple comparisons between the three
groups; Figure 4). The calculated number of sequestered
parasites also increased with severity of the disease. In
‘‘uncomplicated’’ malaria (n ¼ 170) the median (interquartile
range) number of sequestered parasites was ten times lower
than in patients with severe malaria (n¼167): 9.0310
10 (6.73
10
9 to 4.1 3 10
11) compared to 9.1 3 10
11 (6.1 3 10
10 to 3.2 3
10
12) parasites/body (Mann-Whitney U test, p , 0.001). Within
the patients with severe disease, the median (interquartile
range) calculated number of sequestered parasites was twice
as high in the fatal cases than in the patients who recovered:
1.4310
12 (4.3310
11 to 1.4310
13) versus 7.6310
11 (1.2310
10
to 2.7 310
12), but this difference was of borderline statistical
signiﬁcance (Mann-Whitney U test, p ¼ 0.055).
Estimated Total Parasite Biomass in Relation to Other
Markers of Severity
Table 2 shows the associations between the estimated total
parasite biomass and markers of disease severity. For
comparison, the associations based on the calculated total
circulating parasitaemia (from peripheral blood parasitae-
mia) with the same markers are shown. Within the 167
malaria patients with severe disease, 43 patients had cerebral
malaria (deﬁned as a GCS , 11 [10]). These patients had a
higher estimated total parasite biomass than patients without
coma, but also a higher peripheral blood parasitaemia.
Plasma lactate concentrations can be regarded as a crude
measure of the microcirculatory status and have a strong
prognostic signiﬁcance for mortality in severe malaria [15].
An admission plasma lactate concentration above 5 mmol/l
indicates a poor prognosis. Patients with plasma lactate
greater than 5 mmol/l (n ¼ 73) had a signiﬁcantly higher
calculated total body parasite load than patients with a lower
lactate concentration (n¼94): geometric mean (95% CI) 2.83
10
12 (2.0 3 10
12 to 4.1 3 10
12) versus 1.3 3 10
12 (0.9 3 10
12 to
1.8 3 10
12) parasites/body (Student’s t-test, p ¼ 0.002). The
calculated sequestered parasite biomass was also signiﬁcantly
higher in patients with high plasma lactate concentrations
(median 1.6 3 10
12 parasites/body, interquartile range 9.4 3
10
10 to 5.6 3 10
12) than in those with an admission lactate
concentration below 5 mmol/l (median 5.1 3 10
11 parasites/
body, interquartile range 9.1 3 10
9 to 2.0 3 10
12, Mann-
Whitney U test, p ¼ 0.012) (Figure S2). There was a positive
correlation between the calculated sequestered biomass and
the plasma lactate concentration on admission (Spearman
correlation, rs ¼ 0.44, p , 0.001). There was no association
between the circulating parasitaemia (calculated from the
observed peripheral parasitaemia) and plasma lactate con-
centration.
Of the severe malaria patients, 22 had renal failure, deﬁned
as a plasma creatinine above 265 lmol/l and a diuresis of less
than 400 ml/24 h [10]. These patients had a signiﬁcantly
higher estimated geometric mean total parasite load than the
patients without renal failure. It should be noted that the
plasma PfHRP2 half-life was not affected by renal failure in
our pilot study. There was no association between peripheral
blood parasitaemia and renal failure. Jaundiced patients (n ¼
87), deﬁned as those having a total plasma bilirubin above
Figure 4. Total (Log10) Parasite Biomass Estimated from Plasma PfHRP2
Concentrations
Plasma PfHRP2 concentrations (squares) in peripheral blood samples
from 170 patients with uncomplicated malaria, 139 patients with severe
malaria who survived, and 28 patients who died. For comparison the
calculated circulating parasite biomass is also displayed (circles); this was
calculated from the parasitaemia (per 1,000 red blood cells) in a
peripheral blood sample and the estimated total red blood cell mass (see
text for formulas).
DOI: 10.1371/journal.pmed.0020204.g004
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PfHRP2 and Malaria Parasite Biomass42.8 lmol/l [10], had signiﬁcantly higher estimated total
numbers of parasites, but also higher peripheral blood
parasitaemias, than those without jaundice (n ¼ 80). Finally,
a slight but signiﬁcant negative correlation existed between
admission Hct and the calculated log10 total parasite biomass
(Pearson’s method, n¼167, r¼ 0.38, p , 0.001), but there was
also a weak, though signiﬁcant, correlation between Hct and
the log10 total circulating number of parasites (n ¼ 167, r ¼
 0.20, p ¼ 0.008). The group of severe anaemic patients as a
whole did not have a signiﬁcantly higher number of either
circulating or total parasites in their blood (Table 2).
A logistic regression model was constructed with survival as
the dependent variable and with the estimated total parasite
biomass and previously described prognostic criteria in
severe disease as independent variables [10]. Admission
plasma lactate, plasma creatinine, and GCS contributed
signiﬁcantly in the model, but estimated total parasite
biomass did not. This is in contrast to the univariate analysis,
in which the estimated total parasite biomass and the
sequestered parasite biomass (but not peripheral blood
parasitaemia) correlated signiﬁcantly with fatal outcome.
Estimating the Time of Sequestration
It is known from laboratory studies that cytoadherence via
the main adhesion molecule PfEMP1 begins at approximately
12 h of parasite development under febrile conditions, and
50% of the maximum effect is obtained at approximately 14–
16 h of development [16]. This concurs with the stage
distributions of parasites observed in the blood smears of
patients with malaria.
If the time of admission to hospital and stage of parasite
development (in hours) are unrelated, then the overall ratio
of circulating parasites (Pcir) to total parasites (Ptot) in a
population of patients gives the proportion of the asexual life
cycle (assumed to be 48 h) for which parasites are circulating
(Tcir, in hours) at an overall parasite multiplication rate of one
(i.e., steady state). That is,
RPcir
RPtot
  
48 ¼ Tcir ð14Þ
But the parasite numbers are usually expanding, partic-
ularly in uncomplicated malaria before treatment. In the
present model we have assumed a multiplication rate of eight
per cycle for preceding cycles. If the parasite age distribution
is normally distributed with a standard deviation of 4 h, as
estimated previously [9], then this provides 27% more
circulating rings overall in the patient’s parasite population
than if the multiplication rate is one per cycle. That is,
RPcir
1:273RPtot
  
48 ¼ Tcir ð15Þ
If applied to the data from the patients in this series and
this model, then with the assumptions above, the population
mean parasite age at sequestration (Tcir) in uncomplicated
malaria becomes
Tcir ¼
1:731011
1:27ð2:831011Þ
  
48 ¼ 23 h ð16Þ
and for severe malaria is
Tcir ¼
6:131011
1:27ð1:731012Þ
  
48 ¼ 14 h ð17Þ
The estimate in severe malaria is very close to the value
observed in the laboratory. But in severe malaria the next
parasite cycle may not sustain a multiplication rate of eight.
For a multiplication rate of one this value becomes 17 h.
Values between 14 and 17 h are compatible with laboratory
observations, but the estimate of 23 h for patients hospital-
ised with uncomplicated malaria is signiﬁcantly different
from the value observed in ex vivo studies. As it is very
Table 2. Association between the Estimated Total Parasite Biomass Derived from Plasma PfHRP2 and Established Measures of Disease
Severity in Falciparum Malaria
Parameter Trait n
Total Parasite
Biomass Calculated
from Plasma PfHRP2
a
p-Value,
Student’s
t-Test
Total Circulating Parasite
Biomass Calculated from
Peripheral Blood Smear
a
p-Value,
Student’s
t-Test
Outcome Fatal 28 3.4 3 10
12 (1.9 3 10
12 to 6.3 3 10
12) 0.02 8.5 3 10
11 (5.2 3 10
11 to 1.4 3 10
12) n.s.
Surviving 139 1.5 3 10
12 (1.2 3 10
12 to 2.0 3 10
12)8 . 0 3 10
11 (6.4 3 10
11 to 2.0 3 10
12)
GCS ,11 104 3.4 3 10
12 (2.2 3 10
12 to 5.1 3 10
12) 0.002 5.2 3 10
11 (3.3 3 10
11 to 8.0 3 10
11) 0.018
 11 63 1.3 3 10
12 (0.9 3 10
12 to 1.8 3 10
12)9 . 2 3 10
11 (7.2 3 10
11 to 1.2 3 10
12)
Plasma lactate  5 mmol/l 73 2.8 3 10
12 (2.0 3 10
12 to l 4.1 3 10
12) 0.002 1.0 3 10
12 (7.6 3 10
11 to 1.3 3 10
12) n.s.
,5 mmol/l 94 1.3 3 10
12 (0.9 3 10
12 to 1.8 3 10
12)7 . 1 3 10
11 (5.3 3 10
11 to 9.5 3 10
11)
Plasma creatinine  3 mg/dl
b 22 6.2 3 10
12 (2.5 3 10
12 to 12.5 3 10
12) ,0.001 6.9 3 10
11 (3.6 3 10
11 to 1.3 3 10
12) n.s.
,3 mg/dl 145 1.4 3 10
12 (1.1 3 10
12 to 1.8 3 10
12)8 . 3 3 10
11 (6.7 3 10
11 to 1.0 3 10
12)
Plasma bilirubin  2.5 mg/dl 87 3.1 3 10
12 (2.2 3 10
12 to 4.5 3 10
12) ,0.001 1.1 3 10
12 (8.4 3 10
11 to 1.4 3 10
12) 0.004
,2.5 mg/dl 80 1.1 3 10
12 (0.8 3 10
12 to 1.6 3 10
12)6 . 0 3 10
11 (4.3 3 10
11 to 8.2 3 10
11)
Haematocrit ,20%
c 10 4.1 3 10
12 (1.4 3 10
12 to 1.3 3 10
13) n.s. 1.0 3 10
12 (5.8 3 10
11 to 1.8 3 10
12) n.s.
 20% 157 1.7 3 10
12 (1.3 3 10
12 to 2.2 3 10
12)7 . 9 3 10
11 (6.4 3 10
11 to 9.8 3 10
11)
Total parasite biomass derived from plasma PfHRP2 was calculated using the model described in the text. For comparison, the association between the total circulating parasite biomass, based on the observed parasitaemia in the peripheral
blood, and the estimated blood volume (see text) is also shown.
aValues are geometric mean (95% CI).
bIn combination with a diuresis of less than 400 ml/24 h.
cIn combination with a peripheral blood parasitaemia of more than 100,000/ll.
n.s., not significant.
DOI: 10.1371/journal.pmed.0020204.t002
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different between the two groups, this apparent excess of
circulating parasites in uncomplicated malaria suggests that
the assumption of an admission to hospital unrelated to stage
of parasite development is incorrect in this group. This
suggests that schizogony and the consequent pathological
reaction to it are important in stimulating patients with
uncomplicated malaria to come to hospital, whereas referral
of patients with severe malaria is unrelated to the stage of
development of their infecting parasite population.
Discussion
In this study we propose a model to estimate total parasite
biomass using quantitation of a parasite-derived product
(PfHRP2) that is predictably released into peripheral blood
plasma in acute falciparum malaria. The estimated total
parasite biomass was clearly associated with disease severity
and outcome in univariate analyses. In a logistic regression
analysis with outcome as dependent variable, the parasite
load estimates did not predict disease severity better than
conventional measures:GCS, plasma lactate, and serum
creatinine outweighed the contribution of parasite load to
the regression model, suggesting a close causal relationship
between these variables. The estimated total parasite biomass
was also associated with other well-established markers of
severity. In contrast with this, peripheral blood parasitaemia
and the derived total number of circulating parasites were
not associated with disease outcome, nor with other
important measures of severity such as admission plasma
lactate concentrations. It should be noted that some of the
criteria deﬁning severe disease do include the level of the
peripheral blood parasitaemia, which is variably related to
total biomass, although in the model peripheral parasitaemia
was not used in the calculations of parasite biomass. Pre-
treatment with antimalarial drugs affecting PfHRP2 produc-
tion cannot explain the differences in the estimated total
parasite biomass between patients with severe versus un-
complicated malaria: documented pre-treatment was rela-
tively rare (only seven out of 337 patients were pre-treated
with an effective antimalarial drug), and this did not differ
between the groups.
The positive association between sequestered parasite
biomass and disease severity ﬁts with the widely accepted
view that the sequestration of erythrocytes containing the
mature forms of the parasite in the microvasculature of vital
organs is the central pathological process in falciparum
malaria. The greater the number of sequestered parasites, the
more severe is the disease. The cytoadherence of parasitised
erythrocytes to the endothelial lining of the microcirculation
is very efﬁcient. Mature forms of the parasite are rarely seen
in the peripheral blood smear used to assess the patient,
whereas they are central to pathology. Overrepresentation of
late stages in the peripheral blood smear is a prognostic
factor for fatal outcome, because it represents a larger
sequestered parasite biomass [9,11]. Marchiafava and Bignami
were the ﬁrst to observe in their pathological studies of
falciparum malaria that ‘‘malignancy coincides with an
exceptionally abundant quantity of parasitic forms, a
quantity much more abundant—where the cases terminate
fatally—in the blood of the viscera than in the blood of the
ﬁnger’’ [17]. Recent autopsy studies comparing parasite
numbers in brain vessels with peripheral blood parasitaemia
showed a median sequestration index (the ratio of para-
sitaemia in the capillaries and venules compared to that in
the peripheral blood) of 40 (range 1.8–1,500) [18], and a
recent electron microscopic study by Pongponratn et al. in
patients with severe malaria showed a sequestration index of
50 in brain capillaries, but lower indices in other vital organs
[19]. In our study the geometric mean ratio between the total
body parasitaemia and the peripheral blood parasitaemia in
fatal cases was 5.3 (95% CI 2.11 to 13.4) (data not shown). As
this ratio represents the summed estimate of sequestration in
the whole body, it supports the pathological observations of
differential sequestration in the brain and other vital organs.
The calculation of the sequestered biomass also revealed
some limitations of the model we used, since in 22% of
patients a negative value was calculated. This is not
unexpected given that estimates for total parasite biomass
and circulating parasite biomass derive from completely
different parameters, and also that infections can be very
synchronous [9]. Several factors may contribute to inaccur-
acies in the model. The amount of PfHRP2 secreted per
parasite varies between different parasite strains; in our in
vitro study the amount of PfHRP2 secreted per parasite per
erythrocytic life cycle varied between 1.0 3 10
 15 and 11.6 3
10
 15 g. The antigenicity of PfHRP2 is not constant among
parasite isolates because of variation in the expression of
antigenic motifs. The calculations also assume a parasite
multiplication factor of eight, which was derived from
observations in early studies with experimental infection of
humans with P. falciparum as a treatment for syphilis
[14,20,21]. The multiplication factor has a signiﬁcant impact
on the model, as shown in the sensitivity analysis (see Figure
2). With lower multiplication factors, as are likely at high
parasite densities, the contribution of the previous cycle to
the total amount of PfHRP2 will increase, and a similar
plasma concentration of PfHRP2 will represent a lower
number of parasites. Indeed, in our model using a multi-
plication factor of eight, a small number of patients (21 out of
337 patients) had a calculated total number of parasites
exceeding the calculated total number of erythrocytes.
However, if a multiplication factor of one is used in these
patients, no patient has a total body parasitaemia exceeding
100% of the calculated total number of parasites. Variation
in another empirically derived estimate, the plasma half-life
of PfHRP2, also has an impact on the model, but in the
sensitivity analysis the effects were limited. In our study on
plasma PfHRP2 kinetics in 13 patients with falciparum
malaria, the longest plasma half-life was 6.6 d. Doubling the
plasma PfHRP2 half-life in our model with an assumed
multiplication factor of eight reduces the calculated total
parasite load by a factor of 0.55. In high transmission areas,
where partial immunity against the disease develops, clear-
ance of PfHRP2 might be increased in the presence of
antibodies against the protein. The model would thus
underestimate the parasite burden and might need to be
adapted for use in countries in sub-Saharan Africa. Another
assumption made is that the volume of distribution (Vd) of the
plasma PfHRP2 equals the plasma volume, since the size of
the molecule will likely conﬁne its presence to the intra-
vascular compartment. However, binding to other proteins or
cells could increase the apparent Vd, whereas dehydration
could reduce Vd slightly. An increase or decrease in Vd will
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calculated total parasite load. Another source of variation is
the PfHRP2 quantiﬁcation itself. Higher concentrations of
PfHRP2 require larger dilutions, with greater consequent
errors. This may have contributed to the anomaly in those
patients for whom the calculated total body parasitaemia as a
percentage of circulating erythrocytes exceeded 100%.
Finally, the time of blood-taking relative to the parasite
developmental stage will inﬂuence the calculated parasite
biomass. For example, assuming a multiplication factor of
eight, an equal number of parasites will be associated with
almost double the PfHRP2 concentration if the sample is
drawn just before schizont rupture compared with halfway
through the cycle, and the calculated parasite biomass will be
affected by the same factor. P. falciparum infections do tend to
be synchronous [9], and variations in PfHRP2 concentrations,
and thus in the estimated biomass, related to the timing of
the sample in relation to the stage of parasite development
would be more substantial in those patients with synchronous
infections. But the model predictions also provide an answer
to this. By comparing the model-predicted parasite age at
sequestration with the laboratory-observed values for cytoad-
herence, it was evident that in severe malaria the model gave
a very good prediction compared with laboratory ﬁndings
(14–17 h versus 14–16 h). This suggested that admission to
hospital was unrelated to the timing of schizogony in severe
malaria. But in patients with uncomplicated malaria, circu-
lating stages were overrepresented, which suggests that
schizogony, and the host reaction to it, probably do
precipitate hospital admission. This is also supported by the
predominance of parasites of the young ring stage observed
commonly in admission hospital blood smears.
Despite all these potential shortcomings, estimates of the
total parasite load derived from the plasma PfHRP2 concen-
trations were within the range expected and correlated well
with disease severity. In clinical studies of severe malaria,
measurement of plasma PfHRP2 concentrations may be useful
as a research tool to stratify patients by their parasite load.
In summary, this study shows that quantitative measure-
ments of plasma PfHRP2 in patients with falciparum malaria
can be used to estimate the total parasite biomass, a
parameter pivotal in the pathophysiology of the disease. This
calculated total parasite biomass is associated with clinical
measures of the severity of the disease.
Supporting Information
Figure S1. Correlation between Sequestered Parasite Biomass and
Percentage of Late Stages
Scatterplot showing the correlation between the sequestered parasite
biomass (as a percentage of the total parasite biomass) and the
percentage of late stages (trophozoites and schizonts) in an admission
peripheral blood slide in 337 patients with falciparum malaria. The
sequestered and total parasite biomass were derived from plasma
PfHRP2 concentrations as discussed in the text (Spearman correla-
tion, rs ¼ 0.41, p , 0.001).
Found at DOI: 10.1371/journal.pmed.0020204.sg001 (25 KB DOC).
Figure S2. Correlation between PfHRP2-Derived Parasite Biomass
and Plasma Lactate Concentrations
Scatterplot showing the correlation between the PfHRP2-derived
sequestered parasite biomass on admission and admission plasma
lactate concentrations in 337 patients with falciparum malaria
(Spearman correlation, rs ¼ 0.44, p , 0.001).
Found at DOI: 10.1371/journal.pmed.0020204.sg002 (28 KB DOC).
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PfHRP2 and Malaria Parasite BiomassPatient Summary
Background Malaria is caused by parasites of the genus Plasmodium; P.
falciparum causes the most severe disease. After a person is bitten by an
infected mosquito, the parasites enter the person’s red blood cells
(erythrocytes), and then these infected red blood cells get stuck in small
blood vessels, blocking the blood flow and causing many of the
problems associated with malaria. The parasites multiply inside the red
cells, which eventually split and release more parasites.
Why Was This Study Done? It is possible under the microscope to see
the number of parasites in the circulating red blood cells but hard to
measure how many are inside red blood cells stuck in the small blood
vessels at any one time. Knowing the number of parasites blocking up
the blood vessels might give a better idea of how severe the disease a
patient has. An indirect measure of the number of unseen parasites in
the body is a protein, PfHRP2, which the parasites produce and which is
released into the blood when the red blood cells split.
What Did the Researchers Do and Find? They measured the amount of
PfHRP2 in the blood of 337 adult patients with P. falciparum malaria and
looked mathematically to see whether the PfHRP2 measurements could
be linked to the total number of parasites each person had in their body.
They found that people with severe malaria had high total numbers of
parasites hidden in their red blood cells, as measured by the PfHRP2
levels.
What Do These Findings Mean? Further work will need to be done to
reproduce these findings in other groups of people with malaria.
However, estimating the total number of parasites in this way may make
it possible to predict more accurately the likely severity of a person’s
disease.
Where Can I Get More Information Online? The World Health
Organization has a set of Web pages on malaria:
http://www.who.int/topics/malaria/en/
MedlinePlus has an interactive tutorial on malaria:
http://www.nlm.nih.gov/medlineplus/tutorials/malaria/htm/index.htm
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